Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone vs Docetaxel in mCRPC with IDC-P
NCT03356444Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC), sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03356444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356444.